John Lewis
About
John Lewis is from Edmonton, Alberta, Canada. John is currently Bird Dogs Chair in Translational Oncology at University of Alberta, located in Edmonton, Alberta, Canada. John also works as Founder, CEO at Aegis Life, Inc., a job John has held since Sep 2020. Another title John currently holds is Professor at University of Alberta. In John's previous role as a Frank and Carla Sojonky Chair in Prostate Cancer Research at University of Alberta, John worked in Edmonton, Canada Area until Apr 2022. Prior to joining University of Alberta, John was a Founding Chair at Alberta Prostate Cancer Research Initiative and held the position of Founding Chair at Alberta, Canada. Prior to that, John was a CEO at Innovascreen Inc from Aug 2005 to Sep 2019. John started working as Associate Professor at University of Alberta in Edmonton, Canada Area in Jan 2012. From Aug 2006 to Dec 2011, John was Robert Hardie Chair in Translational Prostate Cancer Research at London Health Sciences Centre. Prior to that, John was a Assistant Professor at University of Western Ontario from Aug 2006 to Dec 2011.
John Lewis's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
John Lewis's current jobs
OncoSenX is a late stage pre-clinical cancer company. We target solid tumors based on transcriptional activity using a unique proteo-lipid vehicle gene therapy platform. The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease.
Nanostics is a healthcare biotechnology company focused on development and commercialization of novel, non-invasive diagnostic tests. Our core technology is an advanced liquid biopsy platform that combines an advanced machine learning approach with extracellular vesicle analysis to accurately diagnose disease from a single drop of blood. Our lead product, ClarityDX Prostate, is the most accurate diagnostic test to diagnose aggressive prostate cancer, and is positioned to emerge as the world’s leading diagnostic tool for prostate cancer.
Oisín Biotechnologies is focused on technology that mitigates the effects of age-related diseases to address the damage created by the aging process itself. Our primary focus is killing senescent cells for the treatment and prevention of age-related diseases.
Entos Pharmaceuticals develops next generation nucleic acid-based therapies using the proprietary Fusogenix proteo-lipid vehicle (PLV) drug delivery system. Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. Unlike conventional lipid-based delivery, Fusogenix is well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique formulations to effectively deliver a wide range of genetic therapies, including gene therapy, mRNA, miRNA, RNAi and CRISPR.
John Lewis's past jobs
APCaRI is a multi-disciplinary team of over 300 prostate cancer scientists, physicians, patients, healthcare employees and an international collaborative network focused on clinical translation of innovative prostate cancer research from the laboratory to the clinic. APCaRI has 8 accruing trials open in 2020, including the Alberta Prostate Cancer Biorepository, a prospective study that has recruited more than 4000 patients and amassed over 300,000 biosamples connected with patient-reported and clinical outcomes, and the Alberta Prostate Cancer Registry, a continuously updated database of all Albertan prostate cancer patients linked with those in 14 countries through Movember’s TrueNTH Prostate Cancer Registry.